All posts by imreal

RCH Solutions Joins MassBio, The Boston-area Based Industry Organization Dedicated to Advancing Leadership within the Life Sciences


Logo for RCH Solutions; www.rchsolutions.com

RCH Solutions provides expert Bio-IT services to the Life Sciences.

“We pride ourselves on our ability to prioritize the delivery of results over the fulfillment of service levels, and we look forward to sharing the expertise and insights we’ve gained over our long tenure with the other members of the MassBio community.”

RCH Solutions (RCH), a global provider of Bio-IT computing expertise, has joined Boston-area non-profit, MassBio, dedicated to advancing leadership within the Life Sciences. With a large and growing presence throughout New England, RCH Solutions is eager to deepen its ties and relationships within this respected group as a trusted and established provider of specialty Bio-IT expertise and services within the industry.  

“We’re excited to increase our presence within this important organization in the Life Sciences space,” said Michael Riener, President and CEO of RCH Solutions. “MassBio has been a trusted source for industry advocacy, insights, education and networking, and we’re looking forward to contributing to the important work they do within the Boston-area and beyond.” 

Founded in 1985, MassBio works to advance policy and promote education, while providing member programs, events, industry information, and services for the #1 Life Sciences cluster in the world.

As a trusted provider of specialized computing services exclusively to the Life Sciences for more than 30 years, RCH Solutions currently has hubs in many of the country’s hottest destinations for Life Sciences innovation, including Boston, Philadelphia, La Jolla, and San Francisco. Their highly specialized team has been called upon to help Biotechs and Pharmas across the globe architect, implement, optimize and support compute environments tasked with driving performance for scientific teams conducting research and discovery, and preclinical and clinical development.

With areas of expertise in Cloud Computing, Data Management, Data Science, Emerging Technologies (AI/ML), High-Performance Computing (HPC), Omics and Bioinformatics, Research Application Support, System Administration, and Workflow Optimization, RCH Solutions bridges the gap between IT and R&D Business areas, effectively leveraging innovation in one discipline (IT) to help drive advancement in the other (science). The company has been particularly successful in supporting start-up and emerging Biotechs and Pharmas in the development of scalable and performance-driven compute ecosystems to drive business and scientific goals. 

“In an industry driven by the pursuit of progress, the ability for Biopharma teams to fully harness innovation and technology to support discovery has long been a differentiator,” continues Riener. “We pride ourselves on our ability to prioritize the delivery of results over the fulfillment of service levels and we look forward to sharing the expertise and insights we’ve gained over our long tenure with the other members of the MassBio community.”

To learn more about RCH Solutions, visit http://www.rchsolutions.com.  To learn more about MassBio, visit http://www.MassBio.org.

About RCH Solutions:

RCH Solutions (RCH) is a global provider of Bio-IT expertise, helping Life Sciences and Healthcare companies of all sizes clear the path to discovery. For more than 30 years, RCH has provided focused experience and unmatched specialization designing and deploying cross-functional IT strategies, supporting R&D infrastructure, and offering workflow best practices that solve enterprise and scientific computing challenges.

Share article on social media or email:

Begin to Heal, the Telemedicine Wellness Platform, is acquired by the Institute of Integrative Nutrition, the world’s largest health & nutrition school, in New York


Begin to Heal designed to book sessions with curated holistic wellness and alternative medicine practitioners in the US, was acquired by the Institute of Integrative Nutrition, (IIN), the world’s largest health & nutrition school, based out of New York.

Begin to Heal, the first digital, on-demand wellness platform in the US, designed to book sessions with curated holistic wellness and alternative medicine practitioners was acquired by the Institute of Integrative Nutrition, (IIN), the world’s largest health & nutrition school, based out of New York.

Begin to Heal was a first-of-its-kind telemedicine platform for holistic wellness when it launched in early 2019 in New York. With a wide range of offerings, users could book sessions for various types of holistic wellness services including Acupuncture, Integrative Medicine, Energy Healing, Reiki, Hypnotherapy, Life Coaching, Spiritual Coaching, Naturopathy, Homeopathy, Ayurveda, Therapy and Health & Nutrition Coaching. Begin to Heal’s goal was to help those suffering from stress, anxiety, depression, cancer, addiction, menopause and other health issues to heal naturally with minimal to no side effects, by incorporating natural remedies into their lifestyle.

Begin to Heal enabled video sessions as well as in person sessions through its website and app.

It was also a library of meditations, digital online courses and articles written by experts.

This revolutionary platform had acquired over 15,000 users within a few months of launch. The contemporary design & user interface coupled with the convenience of booking a session in 3 simple clicks, made Begin to Heal an immediate success with customers.

Pooja Khanna, founder of Begin to Heal and a former Fortune 500 strategy and business executive for 13 years with American Express, Microsoft & IBM, is passionate about the wellness, nutrition and mental health space and is looking for her next venture in the UK or India. “I’m on a grass roots mission to put the “care” back in health care, to reunite healing, medicine and spirituality, to inspire people to heal naturally” quoting this dynamic health-tech entrepreneur.

The website is currently under maintenance for upgrade & relaunch.

Share article on social media or email:

Sparian Biosciences Announces Initiation of Phase 1 Clinical Trial of First-In-Class Arylepoxamide Agonist for the Treatment of Pain


“Effective pain management remains a significant challenge across multiple conditions. SBS-1000 has the potential to replace opioids for treating acute and chronic pain and could represent a critically needed innovation,” said Jeffrey B. Reich, MD, Chief Executive Officer, Sparian Biosciences.

Sparian Biosciences, Inc., a clinical-stage CNS-focused biopharmaceutical company, today announced the initiation of a phase 1 clinical trial of SBS-1000, its first-in-class arylepoxamide receptor (AEAr) agonist. SBS-1000 is the first AEAr agonist to receive IND clearance from the FDA and to proceed to a phase 1 human clinical study.

SBS-1000 targets the newly discovered AEA receptor (AEAr) in the pain pathway. In preclinical efficacy studies, SBS-1000 demonstrates potent analgesia in nociceptive, neuropathic, and inflammatory pain models. In addition, in preclinical safety studies, SBS-1000 does not demonstrate respiratory depression, physical dependence, or abuse liability compared to morphine.

“Effective pain management remains a significant challenge across medical and surgical conditions, and SBS-1000 has the potential to replace opioids for the treatment of acute and chronic pain. In the face of the ongoing opiate crisis, we believe SBS-1000 could represent a fundamental and critically needed innovation,” said Jeffrey B. Reich, MD, Chief Executive Officer, Sparian Biosciences. “We have been eager to start the phase 1 trial and hope that the promising preclinical profile of SBS-1000 will translate to human studies.”

The phase 1 clinical trial will primarily evaluate the safety, tolerability, and pharmacokinetics of SBS-1000. In addition, the compound’s analgesic efficacy will be assessed using the Cold Pressor Test as an exploratory endpoint. More details about the trial design will become available on http://www.clinicaltrials.gov.

About Sparian Biosciences

Sparian Biosciences is a clinical-stage CNS-focused biopharmaceutical company committed to developing transformational therapies to address significant medical needs. The company was co-founded by Jeff Reich, MD, and Gavril Pasternak, MD, PhD, and was spun out of Memorial Sloan Kettering Cancer Center (MSKCC). Sparian has five programs that address acute and chronic pain, opioid use disorder, acute opioid overdose, and stimulant use disorder. Sparian is the recipient of two NIH/ NIDA grants worth nearly $20 million. For more information, visit http://www.sparianbiosciences.com/.

Contact Information

Media

Karl Schmieder, Messaginglab

Karl@messaginglab.com

+1. 646.515.3392

Share article on social media or email:

WCG MAGI Clinical Research Conference — 2023 East, May 21-24, 2023


WCG MAGI Clinical Research Conference — 2023 East provides solutions that will take clinical operations, business, and regulatory compliance to new heights.

Long considered the best value in clinical research, WCG MAGI provides attendees access to more than 70 sessions addressing the biggest challenges in clinical trials and showcasing innovation that is igniting change throughout the industry.

Connect with a range of clinical research professionals from sites, pharma, biotech, CROs, academia, government, regulators, and vendors in thoughtfully crafted, collegial interactive sessions, to solve challenges and advance innovation.

Throughout the conference, attendees will get best practices and actionable information they can use to ignite change in clinical research, with:


Fresh sessions are planned on the topics clinical trials practitioners want the most. New sessions include: the FDA’s changes for protecting research participants and how to prepare; must-know aspects of pre-approval access to investigational therapies; incorporating patient voices into drug development; and an interactive ethics session based on Star Trek: The Next Generation.

  • “The Innovation Challenge”


First introduced at WCG MAGI West in October 2022, this challenge features research professionals presenting their latest innovations resulting in improved clinical trial site efficiency, performance or quality.

  • Popular Pre-Conference Sessions


WCG MAGI East is bringing back popular pre-conference sessions, including good clinical practice (GCP) training for those new to clinical research, need re-accreditation or want a thorough refresher. Participants will receive a certificate of training completion. Other pre-conference sessions address research fundamentals and dissecting clinical trial agreements.

Physical Workshop Details:

WCG MAGI Clinical Research Conference — 2023 East

Sunday, May 21 – Wednesday, May 24, 2023

Loews Philadelphia Hotel, Philadelphia, PA

https://wcg.swoogo.com/magi-east23

Tuition:

Physical All-Access Pass:

Early Bird: Register by March 10, 2023 — $1,295

Advance: Register by April 21, 2023 — $1,495

After April 21, 2023 — $1,695

Full access to the event includes all workshops, panel discussions, sessions, meals, and exhibit hall access.

Preconference Workshops Only Pass — $345.00

Includes access to the preconference workshops on Sunday only. Lunch is included.

Exhibit Hall Only – $125.00

Includes access to the exhibit hall only. Lunch is not included.

Easy Ways to Register:

Online: https://wcg.swoogo.com/magi-east23

By phone: 888.838.5578 or 703.538.7600

About WCG MAGI Conferences:

WCG MAGI events connect clinical research professionals who share a deep commitment to ensuring the quality, compliance, and efficiency of clinical research that is needed to advance the delivery of therapies and devices that impact patient’s lives. Professionals who attend WCG MAGI conferences benefit from: comprehensive programing including best-in-class training from seasoned faculty; standardization of best practices for clinical operations, business, and regulatory compliance; innovation forums; and peer-to-peer networking. Most importantly, the WCG MAGI experience strengthens collegiality in a way that ensures the growth and success of clinical research.

Share article on social media or email:

Root Sciences Expands to Thailand – Offers End-to-End Cannabis & Hemp Solutions


Root Sciences Expands to Thailand

“The cannabis and hemp industries are growing rapidly, and we’re committed to providing our customers with the best possible service,” said the CEO of Root Sciences, Fadi Yashruti. “With our expanded capabilities, we can now support businesses worldwide as they enter this burgeoning market.”

Root Sciences is pleased to announce its expansion into Thailand to support the growing cannabis and hemp industries.

Since 2016, Root Sciences has provided equipment solutions for over 500 clients across North America, South America, Europe, and beyond. Backed by years of hands-on experience in both growing and processing, the company is committed to helping businesses deliver top-tier products to their customers.

“The cannabis and hemp industries are growing rapidly, and we’re committed to providing our customers with the best possible service,” said the CEO of Root Sciences, Fadi Yashruti. “With our expanded capabilities, we can now support businesses worldwide as they enter this burgeoning market.”

Root Sciences’ first Thai customer was commissioned in May 2022 and their momentum has continued with several other customers coming on board last year, including Chaophya Abhaibhubejhr Hospital Foundation and Thai Leaf Biotechnology, both leaders in their fields. With additional installations already scheduled for 2023, the company is well-positioned to grow along with the rapidly expanding Thai market.

In new markets, it is crucial for companies to work with knowledgeable partners and quality equipment to ensure minimal time to market and maximum return on investment. As companies move into these markets, they need reliable partners who can provide support through all stages of growth. Root Sciences is the ideal partner for turning those plans into reality.

Root Sciences is the global leader in the distribution of end-to-end equipment and support services for processing facilities in the cannabis and hemp industries, providing premium extraction, distillation, and other post-processing technologies, as well as business planning and lab/facility design and consulting services.

Share article on social media or email:

Attorney Allen Sawyer Gets Charges Dismissed for Bay Area Doctor Involved in Multi-Million Dollar Patients-For-Cash Kickback Scheme


News Image

“This was the largest federal health care fraud case the Bay Area’s ever seen,” said Sawyer. “We are thrilled with the result for my client. Instead of going to prison, he is going home with a clear record and his medical license intact.”

The Law Offices of Allen Sawyer today announce that charges against Dr. T., a client involved in a multi-million-dollar federal health care fraud case (Case # 3:20-cr-00410-MMC), have been dismissed, thanks to the intervention of federal criminal defense attorney Allen Sawyer.

According to a September 5, 2019, press release by the United States Attorney’s Office for the Northern District of California, Dr. T. was among the 13 Bay Area doctors charged with violating Title 42, United States Code, Section 1320a-7b(b)(2)(A) by allegedly accepting kickbacks for providing patient referrals to both Amity Home Health Care and Advent Care, Inc., for home health and hospice services. Statute 42 U.S.C. § 1320a-7b(b)(2)(A) criminalizes intentionally soliciting, offering, or paying a kickback, bribe, or rebate for providing services under a federal health care program. Since it involved patients insured by Medicare, the kickback scheme violated this statute. Defense attorney Allen Sawyer negotiated a deferred prosecution agreement with the U.S. Attorney’s Office, which secured community service for Dr. T., after which the charges against him were dismissed. Sawyer furthermore interceded on his client’s behalf with the Medical Board of California, ensuring the dismissal of all administrative action against Dr. T.’s medical license.

“This was the largest federal health care fraud case the Bay Area’s ever seen,” said Sawyer. “We are thrilled with the result for my client. Instead of going to prison, he is going home with a clear record and his medical license intact.”

About California Defense Attorney Allen Sawyer

With offices in Stockton, San Jose, and Sacramento, The Law Offices of Allen Sawyer comprise unparalleled attorney representation for a range of legal matters across the state. Additionally, Mr. Sawyer can be seen regularly on local television news, handling cases for politicians, celebrities, sports figures, and matters in the public eye.

Sawyer brings over 20 years of experience as a California attorney, including time spent as a prosecutor, to his California defense attorney practice. Misdemeanors and felonies, Allen Sawyer litigates California criminal defense cases including, but not limited to, the following categories:

His distinctive legal experience and his passionate dedication uniquely situate him to provide criminal defense to clients in Stockton, Sacramento, San Francisco, Northern California, Los Angeles, and San Diego. Mr. Sawyer fights for the rights of the accused. For more information or to schedule a consultation, please contact Allen Sawyer directly at (209) 645-0556, or visit the law firm website: https://www.allensawyer.com/.

Press release writing by WebSiteText and Proofreading Services by The Proofreaders

Allen Sawyer recommends Brian Murphy, Wrongful Death Attorney for Elder Abuse & Nursing Home Malpractice Lawsuits.

Share article on social media or email:

Mechanisms Underlying Autoimmunity in Down Syndrome Revealed


The image reflects the model proposed by the Icahn Mount Sinai investigators on autoimmunity in Down syndrome. Malle et al., Nature.

Scientists at the Icahn School of Medicine at Mount Sinai in New York have identified which parts of the immune system go awry and contribute to autoimmune diseases in individuals with Down syndrome. The findings published in the February 22 online issue of Nature [DOI: https://doi.org/10.1038/s41586-023-05736-y .

The work adds to the research team’s findings published in the journal Immunity in October 2022, showing that people with Down syndrome have less frequent but more severe viral infections.

Studying lab specimens from volunteers with Down syndrome, the investigators identified cytokines and a B cell subtype—key players in the adaptive immune response—as the potential culprits for most autoimmunity in people with the disorder.

Strikingly, the researchers found that many people with Down syndrome are in a perpetual state of inflammation comparable to those without Down syndrome who are in intensive care with an acute infection. According to the researchers, this leads to the breaking of immune tolerance, which results in autoimmunity.

“Our findings could be used to test existing therapies not commonly used in persons with Down syndrome and to develop potential therapeutics to alleviate autoimmunity symptoms in individuals with the disorder,” said Dusan Bogunovic, PhD, senior author of the study. “Available drugs such as tocilizumab and a variety of JAK inhibitors could potentially tame this inflammation. And in patients who have elevated autoimmune prone B cells, there is an opportunity to develop therapies targeting this cell type specifically.”

Dr. Bogunovic is a Professor at the Marc and Jennifer Lipschultz Precision Immunology Institute, and the Center for Inborn Errors of Immunity at Icahn Mount Sinai.

Down syndrome, the most common genetic condition diagnosed at birth, is typically caused by triplication of chromosome 21. Among other issues, people with Down syndrome suffer from autoimmunity, including hair loss, skin, gut, and thyroid problems. It is universally present across racial, gender, and socioeconomic lines in approximately 1 in 700 live births, although considerable variation exists worldwide.

“People with Down syndrome are an underserved population worldwide. They require the same level of dedication as all of us. We now have a better understanding of their health and are laying the groundwork to potentially use existing drugs and develop new ones, which could be transformative to their health,” said study first author Louise Malle, an MD/PhD candidate at Icahn Mount Sinai. “We also need to keep in mind that, just like in the general population, not all individuals with the disorder are the same, and there is significant variability.”

Next, the researchers plan to dive deeper into the causes of autoimmunity in Down syndrome and to help propel a formal randomized placebo-controlled clinical trial in which available drugs could best be tested in the clinical setting. In addition, the investigators intend to expand, more broadly, the field’s understanding of the disease.

The paper is titled “Autoimmunity in Down syndrome via cytokines, CD4 T Cells, and CD11c + B cells.”

Additional co-authors are Roosheel S. Patel (Icahn Mount Sinai); Marta Martin-Fernandez (Icahn Mount Sinai); O’Jay Stewart (Icahn Mount Sinai); Quentin Philippot (Inserm, Imagine Institute); Sofija Buta (Icahn Mount Sinai); Ashley Richardson (Icahn Mount Sinai); Vanessa Barcessat (Icahn Mount Sinai); Justin Taft (Icahn Mount Sinai); Paul Bastard (Inserm, Imagine Institute); Julie Samuels (Icahn Mount Sinai); Clotilde Mircher (Institut Jérôme Lejeune); Anne-Sophie Rebillat (Institut Jérôme Lejeune); Louise Maillebouis (Institut Jérôme Lejeune); Marie Vilaire-Meunier (Institut Jérôme Lejeune); Kevin Tuballes (Icahn Mount Sinai); Brad R. Rosenberg (Icahn Mount Sinai); Rebecca Trachtman (Icahn Mount Sinai); Jean-Laurent Casanova (Rockefeller University); Luigi Notorangelo (NIAID/NIH); Sacha Gnjatic (Icahn Mount Sinai); and Douglas Bush (Icahn Mount Sinai).

The work was funded by the National Institute of Allergy and Infectious Diseases Grants R01AI150300, R01AI150300-01S1 and R01AI151029. Louise Maillebouis was supported by the National Institute of Child Health and Human Development T32 training grant T32HD075735. Luigi Notorangelo is supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, NIH.

Dr. Bogunovic is the founder of Lab11 Therapeutics.

-####-

About the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the

eight member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to a large and diverse patient population.

Ranked No. 14 nationwide in National Institutes of Health funding and in the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges, Icahn Mount Sinai has a talented, productive, and successful faculty. More than 3,000 full-time scientists, educators, and clinicians work within and across 34 academic departments and 44 multidisciplinary institutes, a structure that facilitates tremendous collaboration and synergy. Our emphasis on translational research and therapeutics is evident in such diverse areas as genomics/big data, virology, neuroscience, cardiology, geriatrics, and gastrointestinal and liver diseases.

Icahn Mount Sinai offers highly competitive MD, PhD, and master’s degree programs, with current enrollment of approximately 1,300 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. In addition, more than 535 postdoctoral research fellows are in training within the Health System.

A culture of innovation and discovery permeates every Icahn Mount Sinai program. Mount Sinai’s technology transfer office, one of the largest in the country, partners with faculty and trainees to pursue optimal commercialization of intellectual property to ensure that Mount Sinai discoveries and innovations translate into health care products and services that benefit the public.

Icahn Mount Sinai’s commitment to breakthrough science and clinical care is enhanced by academic affiliations that supplement and complement the School’s programs. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai. Additionally, MSIP develops research partnerships with industry leaders such as Merck & Co., AstraZeneca, Novo Nordisk, and others.

The Icahn School of Medicine at Mount Sinai is located in New York City on the border between the Upper East Side and East Harlem, and classroom teaching takes place on a campus facing Central Park. Icahn Mount Sinai’s location offers many opportunities to interact with and care for diverse communities. Learning extends well beyond the borders of our physical campus, to the eight hospitals of the Mount Sinai Health System, our academic affiliates, and globally.

——————————————————-

  • Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Beth Israel; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.


-####

The BTK Inhibitor, Acalabrutinib, Can Reduce or Prevent Allergic Reactions to Peanut During Oral Food Challenges


AAAAI Logo

There are no known therapies that can reliably prevent IgE-mediated allergic reactions. Our study suggests that BTK inhibitors could achieve this protection, with a very quick onset of action.

Acalabrutinib, a BTK inhibitor, can reduce or even eliminate clinical reactions to peanut in adults with peanut allergies undergoing oral food challenges (OFC), according to new research conducted at Johns Hopkins University under the direction of Principal Investigator Melanie C. Dispenza, MD, PhD. Researchers will present the results during the 2023 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI).

Ragha V. Suresh, MD, primary author of the study, explained the rational for the research. “We know that BTK is an essential enzyme involved in signaling through the IgE receptor, which is important in the pathogenesis of allergic reactions. Acalabrutinib is a BTK inhibitor which is FDA-approved for the treatment of B-cell malignancies, but is generally well-tolerated. Therefore, our goal was to re-purpose this drug to see if it could prevent allergic reactions.”

Adults with confirmed peanut allergy were enrolled in an open-label clinical trial. All participants started with a placebo-controlled single-blinded graded OFC to peanut to determine the amount of peanut protein which they tolerated at baseline.

Participants then received four standard doses (100 mg) of acalabrutinib twice a day and underwent a second OFC. Patients’ median tolerated amount of peanut protein was 29 mg at baseline before taking study drug. During OFC while taking acalabrutinib, 7/10 participants were able to tolerate 4,044 mg of peanut protein without clinical reaction, the maximum amount offered in the study protocol. Three of the participants’ tolerance increased significantly, though not to the full peanut protein amount.

Acalabrutinib was also found to abolish all IgE-mediated activation of basophils, a type of allergic cell, in all subjects. No participants experienced any drug-related serious adverse events.

“There are no known therapies that can reliably prevent IgE-mediated allergic reactions,” said Dr. Dispenza. “Our study suggests that BTK inhibitors could achieve this protection, with a very quick onset of action.”

“Our study results could have important ramifications for how we approach more risky procedures related to food allergy,” said Dr. Suresh. “Acalabrutinib could potentially be used as a short-term therapy to make procedures such as immunotherapy and drug desensitizations safer.”

Visit aaaai.org to learn more about anaphylaxis. Research presented at the AAAAI Annual Meeting, February 24-27 in San Antonio, Texas, is published in an online supplement to The Journal of Allergy and Clinical Immunology.

The American Academy of Allergy, Asthma & Immunology (AAAAI) is the leading membership organization of more than 7,100 allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. The AAAAI is the go-to resource for patients living with allergies, asthma and immune deficiency disorders. Established in 1943, the AAAAI has more than 7,100 members in the United States, Canada and 72 other countries. The AAAAI’s Find an Allergist/Immunologist service is a trusted resource to help you find a specialist close to home.

Share article on social media or email:

HMP Global earns second straight New Jersey ‘Top Workplaces’ honors based on employee feedback


Logos for HMP Global and Top Workplaces Award

For the second year in a row, HMP Global has earned a New Jersey Top Workplaces award based solely on the feedback from employees.

HMP Global, the leading healthcare events and education company, earned a Top Workplaces 2023 award from NJ Advance Media and NJ.com for the second straight year, a recognition based solely on feedback from its employees. It is one of only 83 companies statewide to earn the designation this year.

The anonymous survey administered by employee engagement technology company Energage, LLC measures 15 workplace culture drivers that are critical to organizational success, including alignment, execution of goals, and connection. Of the hundreds of companies that participated this year, only a limited number of companies earned the Top Workplaces designation due to the award’s rigorous high standards.

Headquartered in Pennsylvania, HMP Global also operates a New Jersey office and produces nearly 500 conferences and educational events virtually and in-person throughout the United States and the world. Additionally, HMP Global Learning Networks provide clinically relevant, evidence-based content to keep healthcare professionals up to date in a range of therapeutic areas.

Jeff Hennessy, HMP Global Chairman and CEO, said the Top Workplaces award is one indicator of the company’s concerted efforts to foster a positive work culture, and will help the company continue to attract top-tier talent as it grows.

“Receiving the Top Workplaces award for the second year in a row is a testament to our dedication to employee satisfaction,” Hennessy said. “We strive to be the employer of choice in our industry, and we actively use our employee feedback to address any issues as they arise. HMP Global has a 38-year history of excellence, and we continue to focus on outcomes as we grow.”

The company recruits locally and virtually, seeking out candidates from a broad talent pool. HMP Global’s workforce is largely remote, with employees located in 30 different states, but it hosts in-person networking events for employees multiple times a year. Among its retention efforts, HMP Global also offers both live and virtual management training programs to help employees grow and develop leadership skills. Its record of employee retention is strong, with a 7-year average length of service.

“The importance of a positive work environment for worker recruitment and retention cannot be overstated,” said Anthony Mancini, Chief Human Resources Officer and EVP of Operations at HMP Global. “Our hard work in creating and sustaining a culture that fosters professional growth and learning, coupled with recognitions of the efforts our employees make, has been recognized through this award. The Top Workplaces award highlights the dedication of our leadership and our devoted team.’

For more information about careers at HMP Global or to apply for open positions, visit hmpglobal.com/careers.

About HMP Global

HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

Share article on social media or email:

New Program Bolsters Healthcare Startup Ecosystem in Orange County and Southern California


News Image

Tech Coast Angels (TCA) and the Octane LaunchPad SBDC (Small Business Development Center) have established a new joint program, called Orange County Healthcare Innovation Table (OC HiT).

The joint program, referred to as Medical Mondays, was created to advance the development, implementation, funding, and commercialization efforts of healthcare startups, primarily in Orange County and Southern California. This collaboration aims to support and guide startups in being better positioned scientifically, technically, clinically, and financially to enter the marketplace.

OC HiT is collaborating with two renowned healthcare systems: CHOC Children’s Hospital of Orange County (CHOC) through its Research Institute and Hoag, which provide expertise and support for clinical development process.

Consultants at Octane’s LaunchPad SBDC, together with TCA, Hoag and CHOC, assess and validate startups’ technologies and commercialization roadmaps to more quickly secure funding and clinical adoption.

OC HiT Medical Mondays were successfully piloted in 2022, engaging 80 startups. The program resulted in 30 startups being matched and introduced to a clinical or hospital partner; seven startups were offered clinical collaborations, and 22 were invited to apply to at least one of the TCA networks.

Ideal candidates for Medical Mondays will have an established team, are beyond the ideation stage, and are either working on or have completed a proof of concept or early animal trials. The program will be fluid and adapt to each startup’s particular needs and circumstances. Candidates may be from outside of California and the U.S., although these candidates should have plans for a U.S. operation, ideally in or planned to be in the Southern California region.

The LaunchPad SBDC team will review start-up applications, pre-qualify them for joint reviews, and provide LaunchPad SBDC consultants to help with business strategy, planning, operations, funding, and development of a pitch deck if a startup doesn’t currently have one. Startups also will have the option to participate in Octane programs and conferences.

The Hoag and CHOC team will provide feedback by assessing the clinical problem and need, prototype application and requirements as well as regulatory strategy. The team’s goal is to ensure that startup innovations are attractive to hospitals and physician groups as future customers. The team will be able to potentially engage Hoag and CHOC resources, research and clinicians who can serve as subject matter experts.

The TCA team will focus on investability and also be available to review applications submitted by the company as well as potentially be a source of funding through one of the TCA networks. TCA experts may advise on the technology, market size, share, growth, and financial projections.

For more information or to participate, please contact Laura Beken, laura.beken@techcoastangels.com

About TCA

Since its inception in 1997, Tech Coast Angels (TCA) has invested more than $261 million in more than 520 companies and has helped attract more than $1.7 billion in additional capital/follow-on rounds. The Tech Coast Angels network includes TCA Los Angeles, TCA Orange County, TCA Inland Empire, and licensees including Pasadena Angels and MEDA Angels. One of the largest and most active angel investor groups in the nation, TCA and its affiliate member networks include more than 400 members, and are a leading source of funding for seed-stage and early-stage companies. TCA members are founders and business leaders, all of whom are accredited investors with extensive knowledge in the investment process and world-class business practices. That real-world experience allows TCA members to provide companies with benefits beyond capital: counsel, mentoring, and access to an extensive network of investors and other resources. http://www.techcoastangels.com

About LaunchPad SBDC

LaunchPad SBDC is a non-profit and grant-funded late-seed/early VC business startup accelerator focusing on tech, medtech, aesthetic innovation, ophthalmology, cardiology and climate tech. Startups work with LaunchPad SBDC consultants to develop and accelerate their capital funding strategy

About Hoag R&D

At Hoag, the Center for Research and Education is conducting several hundred clinical trials with governmental (e.g., NIH) and biotech industry sponsors, including Phase 1 cancer and Alzheimers therapeutics. Early stage companies in the pharma, device, software, and AI space find Hoag’s clinical research and development capabilities a seamless and highly efficient way of translating new technology to the clinical bedside stage. Hoag understands the critical importance in allowing our community’s patients access to the most novel therapies once safety is assured through the FDA approval process, and then documenting the efficacy of such innovation in a real world clinical setting, where continuous improvement of such advancements can occur to benefit all of healthcare.

About Hoag

Hoag is a nonprofit, regional health care delivery system in Orange County, California. Delivering world-class, comprehensive, personalized care, Hoag consists of 1,800 top physicians, 15 urgent care facilities, 10 health & wellness centers, and two award-winning hospitals. Hoag offers a comprehensive blend of health care services that includes six institutes providing specialized services in the following areas: cancer, digestive health, heart and vascular, neurosciences, women’s health, and orthopedics through Hoag’s affiliate, Hoag Orthopedic Institute, which consists of an orthopedic hospital and four ambulatory surgical centers. Hoag is the highest ranked hospital in Orange County by U.S. News & World Report and the only OC hospital ranked in the Top 10 in California, as well as a designated Magnet® hospital by the American Nurses Credentialing Center (ANCC). For more information, visit hoag.org.

About CHOC Research

At CHOC, we know that research saves lives. That’s why our Research Institute has more than 500 research studies in more than 30 specialties to provide your child with access to leading-edge treatments. Our scientists translate the latest advances in molecular profiling, including whole genome sequencing, to meet the individual needs of our patients at every stage of their young lives —from infancy through adolescence. We conduct research directly with children and adolescents in a facility devoted exclusively to the care, quality of life, rights, and safety of children of all ages.

About Children’s Hospital of Orange County

Children’s Hospital of Orange County (CHOC), a pediatric healthcare system based in Orange County, California, is committed to being a leading destination for children’s health by providing exceptional and innovative care. CHOC’s growing community includes two state-of-the-art hospitals in Orange and Mission Viejo and a regional network of primary and specialty care clinics serving children and families in four counties. CHOC offers several clinical programs of excellence providing the highest levels of care for the most serious pediatric illnesses and injuries, physical and mental. CHOC’s research and innovation institutes are focused on translating real patient needs into real-world treatments so every child can live the healthiest and happiest life possible.